Cargando…

Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB

BACKGROUND: HIV-infection leads to a higher risk of progression from asymptomatic, non-transmissible latent tuberculosis infection (LTBI) to active tuberculosis (TB). Specific comorbid medical risk factors increase this risk which can be decreased by successfully treating LTBI. METHODS: We compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Scolarici, Michael, Dekitani, Ken, Chatterjee, Soumya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631657/
http://dx.doi.org/10.1093/ofid/ofx163.413
_version_ 1783269525900230656
author Scolarici, Michael
Dekitani, Ken
Chatterjee, Soumya
author_facet Scolarici, Michael
Dekitani, Ken
Chatterjee, Soumya
author_sort Scolarici, Michael
collection PubMed
description BACKGROUND: HIV-infection leads to a higher risk of progression from asymptomatic, non-transmissible latent tuberculosis infection (LTBI) to active tuberculosis (TB). Specific comorbid medical risk factors increase this risk which can be decreased by successfully treating LTBI. METHODS: We compared risk of progression between HIV infected and uninfected adults seen at the Saint Louis University hospital from 2010 to 2015 using a validated online calculator (tstin3d.com). We also recorded information on prescribing practices and treatment completion rates in the two groups. RESULTS: Of 125 patients included, 10 had HIV, 10 AIDS, and 105 HIV-uninfected. The median annual TB-risk amongst the three groups was 8% (3–8%), 22% (21–25%), and 0.5% (0–6%) respectively. Smoking, recent TST/IGRA conversion, and diabetes were more prevalent among HIV/AIDS patients. Nine months of INH was most commonly prescribed for both HIV/AIDS (85%) and HIV-uninfected groups (45%). Of concern, were the equivalent rates of LTBI treatment non-completion seen between HIV/AIDS than HIV-uninfected patients (35% vs. 34%). CONCLUSION: TSTin3D.com can facilitate increased provider awareness of TB activation risk factors and can quantitate risk of reactivation. We are currently implementing the calculator in the clinic to prospectively study how risk stratification can alter treatment choices for LTBI patients at highest risk for progression to TB. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-5631657
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56316572017-11-07 Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB Scolarici, Michael Dekitani, Ken Chatterjee, Soumya Open Forum Infect Dis Abstracts BACKGROUND: HIV-infection leads to a higher risk of progression from asymptomatic, non-transmissible latent tuberculosis infection (LTBI) to active tuberculosis (TB). Specific comorbid medical risk factors increase this risk which can be decreased by successfully treating LTBI. METHODS: We compared risk of progression between HIV infected and uninfected adults seen at the Saint Louis University hospital from 2010 to 2015 using a validated online calculator (tstin3d.com). We also recorded information on prescribing practices and treatment completion rates in the two groups. RESULTS: Of 125 patients included, 10 had HIV, 10 AIDS, and 105 HIV-uninfected. The median annual TB-risk amongst the three groups was 8% (3–8%), 22% (21–25%), and 0.5% (0–6%) respectively. Smoking, recent TST/IGRA conversion, and diabetes were more prevalent among HIV/AIDS patients. Nine months of INH was most commonly prescribed for both HIV/AIDS (85%) and HIV-uninfected groups (45%). Of concern, were the equivalent rates of LTBI treatment non-completion seen between HIV/AIDS than HIV-uninfected patients (35% vs. 34%). CONCLUSION: TSTin3D.com can facilitate increased provider awareness of TB activation risk factors and can quantitate risk of reactivation. We are currently implementing the calculator in the clinic to prospectively study how risk stratification can alter treatment choices for LTBI patients at highest risk for progression to TB. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5631657/ http://dx.doi.org/10.1093/ofid/ofx163.413 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Scolarici, Michael
Dekitani, Ken
Chatterjee, Soumya
Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB
title Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB
title_full Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB
title_fullStr Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB
title_full_unstemmed Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB
title_short Using a Validated Calculator to Assess the Risk of Disease Progression and Treatment Completion in Patients with Human Immunodeficiency Virus Infection and Latent TB
title_sort using a validated calculator to assess the risk of disease progression and treatment completion in patients with human immunodeficiency virus infection and latent tb
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631657/
http://dx.doi.org/10.1093/ofid/ofx163.413
work_keys_str_mv AT scolaricimichael usingavalidatedcalculatortoassesstheriskofdiseaseprogressionandtreatmentcompletioninpatientswithhumanimmunodeficiencyvirusinfectionandlatenttb
AT dekitaniken usingavalidatedcalculatortoassesstheriskofdiseaseprogressionandtreatmentcompletioninpatientswithhumanimmunodeficiencyvirusinfectionandlatenttb
AT chatterjeesoumya usingavalidatedcalculatortoassesstheriskofdiseaseprogressionandtreatmentcompletioninpatientswithhumanimmunodeficiencyvirusinfectionandlatenttb